Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Meridian Bioscience Q3 EPS $0.16, Inline, Sales $67.80M Beat $66.82M Estimate

Meridian Bioscience (NASDAQ:VIVO) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 27.27 percent decrease over earnings of $0.22 per share from the same period last year.
byBenzinga Newsdesk
August 5, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Meridian Bioscience (NASDAQ:VIVO) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 27.27 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $67.80 million which beat the analyst consensus estimate of $66.82 million by 1.47 percent. This is a 6.75 percent increase over sales of $63.51 million the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

What’s Going On With Revolution Medicines Stock?

By Erica Kollmann
April 10, 12:20 PM
Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The company also announced the publication of two peer-reviewed research papers in "Nature" Tuesday. The first paper highlights the discovery and preclinical characterization of RMC-7977, and the second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.

RVMD